SkinCeuticals Blemish + Age Cleansing Gel

Product Overview

SkinCeuticals Blemish + Age Cleansing Gel addresses the clinical overlap between acne-prone skin and the early signs of intrinsic and extrinsic ageing — a combination frequently encountered in patients aged 25-45. The 12% tri-acid complex combines three mechanistically complementary exfoliating agents: capryloyl salicylic acid (LHA, lipo-hydroxy acid), glycolic acid, and salicylic acid. LHA is a lipophilic derivative of salicylic acid with a larger molecular size that penetrates the stratum corneum more gradually, providing precise, layer-by-layer exfoliation without the erythema risk associated with high-concentration salicylic acid. LHA exerts comedolytic activity by targeting the follicular infundibulum, disrupting the abnormal follicular hyperkeratinisation central to comedone formation (Kircik, J Drugs Dermatol, 2012).

Glycolic acid (alpha-hydroxy acid) in the complex accelerates the natural turnover of superficial corneocytes through corneodesmolysis, improving textural irregularity, roughness, and hyperpigmentation associated with photoageing and post-acne scarring. Salicylic acid (beta-hydroxy acid) adds sebum-solubilising and anti-inflammatory activity relevant to the pathogenesis of papulopustular acne. The three acids act in synergy across the epidermis and follicular epithelium, providing a more comprehensive exfoliating action than any single acid at equivalent concentration. Glycerin and sorbitol are included as humectant counterweights to minimise barrier disruption. The product is formulated as a rinse-off gel, limiting acid contact time to approximately 30-60 seconds during the cleansing step, which reduces cumulative irritation risk compared to leave-on exfoliants.

Specifications

Clinical Indications and Key Applications

• Mild to moderate comedonal and papulopustular acne (Grade I-II, IGA/GAGS classification) where the LHA and salicylic acid components target follicular hyperkeratinisation and sebum accumulation as primary pathogenic drivers
• Concurrent acne and early photoageing in patients aged 25-45, where glycolic acid addresses textural irregularity and early fine lines while the comedolytic acids manage active blemishes — a combination not addressed by single-mechanism cleansers
• Post-inflammatory hyperpigmentation (PIH) and uneven skin tone following acne lesion resolution, where regular glycolic acid exposure accelerates turnover of pigmented corneocytes
• Pre-procedural preparation for in-clinic AHA/BHA chemical peels or laser resurfacing in patients with active comedonal acne, as a preseasoning step to promote epidermal uniformity
• Oily and congested skin with enlarged pores, where combined salicylic acid and LHA activity reduces visible pore size by decongesting the follicular infundibulum and regulating sebum production
• Maintenance phase after completion of topical retinoid or benzoyl peroxide-based acne treatment courses, as a long-term exfoliating cleanser to prevent comedone recurrence

Frequently Asked Questions

Q: What is LHA (capryloyl salicylic acid) and how does it differ from regular salicylic acid?
A: Lipo-hydroxy acid (LHA) is a lipophilic derivative of salicylic acid produced by the esterification of salicylic acid with a fatty acid chain (capryloyl). The larger molecular size and increased lipophilicity of LHA slows its epidermal penetration relative to salicylic acid, resulting in more targeted, layer-by-layer exfoliation predominantly at the follicular infundibulum with less systemic irritation risk. Clinical studies (Kircik, J Drugs Dermatol, 2012) demonstrated equivalent comedolytic efficacy to salicylic acid at lower irritation rates, making LHA preferable for patients with mild-to-moderate sensitive or reactive acne-prone skin.

Q: Can this cleanser be used with topical retinoids or benzoyl peroxide?
A: Yes, but initiation sequencing matters. When starting a retinoid (e.g., adapalene, tretinoin, or SkinCeuticals Retinol 0.5), introduce the Blemish + Age Cleansing Gel first and wait until skin is tolerant before adding the retinoid. Concomitant use of three exfoliating agents (cleanser acids + retinoid + benzoyl peroxide) may precipitate over-exfoliation, manifesting as erythema, scaling, and barrier compromise. Apply benzoyl peroxide or retinoid after cleansing, not concurrently in the same step. Dermatological supervision is recommended for patients with moderate-to-severe acne managing multiple actives.

Q: Is this suitable for dry or sensitive skin?
A: Blemish + Age Cleansing Gel is formulated for oily, combination, and acne-prone skin types. Patients with confirmed dry skin or sensitised barrier (rosacea, eczema, post-procedure) should not use this cleanser as a primary step; the 12% acid complex may exacerbate barrier disruption. For sensitive or dry skin within the SkinCeuticals range, the Gentle Cream Cleanser or Soothing Cleanser are appropriate alternatives. Mixed skin-type patients with oily T-zone and drier cheeks may tolerate once-daily use in the T-zone only if double-cleansing for the full face.

Q: How does this compare to the Glycolic Renewal Cleanser?
A: Glycolic Renewal Cleanser (8% FAV glycolic acid at pH 3.5) is optimised for texture irregularity, dullness, and PIH in non-acne skin types. Blemish + Age Cleansing Gel (12% tri-acid LHA/glycolic/salicylic) is specifically formulated for oily and acne-prone skin where both comedolytic and antiageing exfoliation are required. For patients with confirmed comedonal acne, Blemish + Age Cleansing Gel is the more clinically appropriate choice. For patients without active acne seeking exfoliation and anti-ageing, Glycolic Renewal Cleanser is the appropriate selection.

Q: Is SkinCeuticals Blemish + Age Cleansing Gel available for purchase in Singapore?
A: Yes. EMIS supplies the full SkinCeuticals range to authorised aesthetic clinics, dermatology practices, and individual purchasers in Singapore. Genuine SkinCeuticals products are sourced from the authorised distribution network, ensuring compliance with the brand stability and potency standards from manufacturing to delivery. Purchasing through non-authorised channels carries risks of compromised product integrity and invalidated clinical efficacy claims.